Overview of Nyxoah's Genio Therapy
Nyxoah is a pioneering medical technology company specializing in innovative treatments for Obstructive Sleep Apnea (OSA) through advanced neuromodulation techniques. Its flagship product, the Genio® system, offers a breakthrough, leadless, and battery-free therapy aimed at enhancing patient outcomes in managing OSA, a significant condition impacting millions worldwide.
Significant Medicare Reimbursement Changes for 2026
Recently, the U.S. Centers for Medicare & Medicaid Services (CMS) announced critical updates through the final CY2026 Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgery Center (ASC) Rule. This new regulation assigns CPT Code 64568, which pertains to Genio hypoglossal nerve stimulation (HGNS) implants, to New Technology Ambulatory Payment Classification (APC) 1580. This adjustment is expected to positively impact the commercial rollout of Genio® in the U.S. market, as hospitals and ASCs can now benefit from significantly increased reimbursements.
Reimbursement Rates Rise
Under the finalized CMS rule, effective January 1, 2026, the reimbursement for the Hospital Outpatient Department (HOPD) for CPT 64568 will rise to approximately $45,000 — a remarkable 48% increase compared to the previous year. Ambulatory Surgery Centers (ASC) are set to receive $42,373 for the same procedure, reflecting a 58% increase. Such enhancements provide a more solid economic basis for the adoption of Genio® therapy across U.S. medical facilities.
Benefits of Genio Therapy Adoption
The updates are not merely a financial boost; they represent a shift in how hypoglossal nerve stimulation is recognized for its added value in treating obstructive sleep apnea. The decision by CMS indicates a growing acceptance of Genio's therapy approach, which is both timely and essential for expanding patient access and increasing procedure throughput. As more Medicare-heavy institutions adopt this therapy, patients can expect enhanced opportunities for treatment.
Opportunities for Expansion
The nature of Genio®'s single-incision procedure aligns well with the capabilities of Ambulatory Surgery Centers (ASCs), enabling facilities to diversify their offerings. The increase in ASC facility payment opens avenues for broader therapy expansion, allowing more patients to benefit from this innovative treatment. Olivier Taelman, CEO of Nyxoah, highlighted that CMS's decision lends a favorable perspective to hypoglossal nerve stimulation, affirming its status as a key therapeutic option for OSA management.
About Nyxoah
Founded with a clear mission, Nyxoah strives to transform the treatment landscape for those suffering from OSA. Their Genio system, approved under the European CE Mark in 2019, has demonstrated promising results in clinical trials, particularly in the recent BETTER SLEEP study. This research resulted in the expansion of indications for patients experiencing complete concentric collapse, a complication that competitors' therapies often cannot address. Moreover, Nyxoah's recent FDA approval for moderate to severe adult OSA patients further strengthens their position in the healthcare market.
Company Milestones and Future Plans
Nyxoah completed successful initial public offerings on Euronext Brussels and NASDAQ, signaling robust interest in innovative healthcare solutions. With continuous advancements in their offerings, Nyxoah remains committed to enhancing patient experiences and outcomes through dedicated research and development efforts.
Frequently Asked Questions
1. What is Nyxoah's Genio therapy?
Genio therapy is a leadless, battery-free hypoglossal neurostimulation system aimed at treating obstructive sleep apnea.
2. How has Medicare impacted Nyxoah's market?
Medicare's increased reimbursement rates for Genio® therapy are expected to boost its adoption across hospitals and ASCs.
3. What is the significance of CPT Code 64568?
CPT Code 64568 is specifically for Genio hypoglossal nerve stimulation implants and will see increased reimbursement rates starting in 2026.
4. When was Genio approved?
Genio received its European CE mark in 2019, with FDA approval following in 2025 for certain patient types.
5. How does Nyxoah's system differ from competitors?
Nyxoah's leadless and battery-free design offers a unique benefit, especially for patients unable to use traditional therapies.
